Two Versus Three Induction Cycles in Nasopharyngeal Carcinoma: Equal Survival, More Toxicity
This retrospective propensity-matched analysis suggests a third cycle of TPF induction adds hematologic and gastrointestinal toxicity without a detectable survival gain in stage III–IVa nasopharyngeal carcinoma, but it cannot replace a randomized comparison.
📅 Journal publication: Jul 31, 2026·Last updated: Nov 3, 2026
Two chemo cycles reduce toxicity in nasopharyngeal cancer.
Determining the optimal number of chemotherapy cycles could improve treatment tolerability in nasopharyngeal carcinoma. Two cycles of induction chemotherapy showed similar survival outcomes but lower toxicity compared to three cycles. This study suggests fewer induction chemotherapy cycles might minimize toxicity with no loss in efficacy, but it is limited by its retrospective design. Two chemo cycles may suffice for advanced nasopharyngeal carcinoma, reducing toxicity.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Xie R, Lin X, Li Q, Pan J, Xie K, Chen J, Zhang Y, Chen C, Zhan Y
Citation:Xie R, Lin X, Li Q, et al. Comparative efficacy and toxicity of two versus three induction chemotherapy cycles in locally advanced nasopharyngeal carcinoma: a propensity score matching analysis. BMC cancer. 2026;26(1). doi:10.1186/s12885-026-16655-2